% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schubert:304434,
      author       = {M.-L. Schubert and P. Dreger and M. Schmitt$^*$},
      title        = {{C}himeric antigen receptor {T}-cells for patients with
                      hematologic malignancies. [{C}himäre
                      {A}ntigen-{R}ezeptor-{T}-{Z}ellen für {P}atientinnen und
                      {P}atienten mit hämatologischen {N}eoplasien].},
      journal      = {Zeitschrift für Rheumatologie},
      volume       = {84},
      number       = {8},
      issn         = {0340-1855},
      address      = {Darmstadt},
      publisher    = {Steinkopff},
      reportid     = {DKFZ-2025-01847},
      pages        = {601-611},
      year         = {2025},
      note         = {2025 Oct;84(8):601-611},
      abstract     = {The targeted and personalized cell and gene therapy with
                      autologous chimeric antigen receptor (CAR) transduced
                      T‑cells (CAR T‑cells) has become established as the
                      standard therapy for patients with B‑cell diseases, such
                      as CD-19 positive leukemia and lymphomas and B‑cell
                      maturation antigen (BCMA) positive multiple myeloma (MM).
                      This therapy has been approved in Europe since 2018 and is
                      administered in more than 50 clinics in Germany. With
                      increasing experience and expertise in understanding of the
                      principles of action and underlying mechanisms as well as
                      mitigation of side effects have significantly improved. In
                      the near future expansion of CAR T‑cell applications are
                      to be expected, aimed at addressing further targets and
                      therefore other disease entities. Currently, the indications
                      have already expanded beyond hematology and oncology to
                      rheumatology, neurology and other fields.},
      subtyp        = {Review Article},
      keywords     = {B‑cell diseases (Other) / CAR T‑cells (Other) / Cell
                      and gene therapy (Other) / Indications (Other) / Principle
                      of action (Other)},
      cin          = {HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)HD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40906189},
      doi          = {10.1007/s00393-025-01703-2},
      url          = {https://inrepo02.dkfz.de/record/304434},
}